Please fax all pages of completed form to your team at 808.650.6487.

To reach your team, call toll-free 808.650.6488.

You can now monitor shipments and chat online if you have questions. Go to MyAccredoPatients.com to log in or get started.

Prescription & Enrollment Form

KisunlaTM (donanemab-azbt)



Four simple steps to submit your referral.

■ Patient Information	on			de copies of front and bac tion insurance cards.	. o. un modicui
New patient Current patient					
Patient's first name		Last r	name		Middle initial
Preferred patient first name			Preferred patient	last name	
Sex at birth: Male Female Ge	nder identity	Pro	nouns	Last 4 digits o	f SSN
Date of birthStree	et address				_ Apt #
City		State		Zip _	
Home phone	Cell phone		Email a	address	
Parent/guardian (if applicable)					
Home phone	Cell phone		Email a	address	
Alternate caregiver/contact					
Home phone	Cell phone		Email a	address	
OK to leave message with alternate	caregiver/contact				
Patient's primary language: Englis	h Other If other	, please specify			
2 Prescriber Inform				mpleted to expedite presc	
Date T Office/clinic/institution name					
Prescriber info: Prescriber's first name					
Prescriber's title					
Office phone					
Office contact and title					
Office street address					
City					
Infusion location: Patient's home					
	'`_' _'`_'`'`		Clinic/hospital af	·	
Infusion info: Infusion site name Site street address					. #
City					
Infusion site contact					·
3 Clinical Informati		3	rax	EIIIaII	
Primary ICD-10 code (REQUIRED): _			•	, ,	
Is the patient currently on therapy?			tried/failed:		
Patient wt Date w NKDA Known drug allergies					
Concurrent meds					

Patient's first name	Last name	Middle initial Date of birth
Prescriber's first name	Last name	Phone
Diagnosis: G30.0 Alzheimer's disease with early onset G30.1 Alzheimer's disease with late onset G30.8 Other Alzheimer's disease G30.9 Alzheimer's disease, unspecified G31.84 Mild cognitive impairment, so stated Other:	Evidence of PET scar CSF sam Plasma s	ple

4 Prescribing Information

Medication/Strength	Directions	Quantity/Refills
Kisunla™ (donanemab-azbt) 350mg/20mL (17.5mg/mL) single-dose vial	Starting Dose: Infuse 700mg (two vials) intravenously over approximately 30 minutes once every 4 weeks for Infusions 1, 2, and 3 If patient needs partial starting dose, indicate what is needed:	2 vials/28 days supply Refills: 2 Other
Medicare beneficiaries (required by CMS): NCT registry number:	Infusion 2 and Infusion 3 Infusion 3 only	
CED submission number:	Maintenance Dose: Infuse 1400mg (four vials) intravenously over approximately 30 minutes at infusion 4 and then once every 4 weeks thereafter	4 vials/28 days supply Refills: Other
CED submission date:	Observe the patient post-infusion for a minimum of 30 minutes to evaluate for infusion reactions and hypersensitivity reactions.	
CED Registry Link: https://qualitynet.cms.gov/ alzheimers-ced-registry	Note: MRIs must be obtained by prescriber prior to initial infusion and before Infusions 2, 3, 4 and 7 to monitor for ARIA, and as needed if symptoms consistent with ARIA occur.	

Dispense needles, syringes, ancillary supplies and home medical equipment necessary to administer medication.

If shipped to physician's office, physician accepts on behalf of patient for administration in office.

Prescriber's signature required (sign below) (Physician attests this is his/her legal signature. NO STAMPS)

SIGN	
HERE	

Date	Dispense as written	Date	Substitution allowed

The prescriber is to comply with his/her state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to the prescriber.

